


# CEREVEL THERAPEUTICS

*Unraveling the Mysteries  
of the Brain*



# Transforming What is Possible in Neuroscience

**Cerevel is working to unravel the mysteries of the brain and bring forward new treatment options for people living with some of the most devastating neuroscience diseases**

- Cerevel is a purpose-built company with a team of seasoned leaders and neuroscience drug developers who combine a nimble, results-driven biotech mindset with expertise in clinical design and execution

---

- Headquartered in Cambridge, MA, Cerevel is developing a portfolio of potential CNS therapies licensed from Pfizer and enriching the pipeline with a vibrant early discovery portfolio

---

- Cerevel is focused on the development of novel therapies, combining deep understanding of neurocircuitry, with receptor subtype selectivity and differentiated pharmacology

---

- Cerevel is led by a strong management team that brings to the organization a combined track record of more than 20 prior drug approvals and launches

---

- Since its founding in 2018, Cerevel has delivered 2 successful data readouts, initiated 8 clinical trials, filed 5 INDs, and raised over \$1 billion in capital through private financings, a go-public transaction, public offerings, and non-dilutive financing

# CEREVEL IS BUILDING OUT ITS NEUROSCIENCE EXPERTISE ACROSS THE CONTINUUM OF DRUG DISCOVERY AND DEVELOPMENT

---



Chemistry



Pharmacology



Translational  
Medicine



Clinical Trial  
Execution



Regulatory  
Know-How



Budding Commercial  
Presence

*Our mission is to become the premier neuroscience company as we seek to push boundaries, develop solutions and transform lives*

# Our Differentiated Approach to Treating Neuroscience Diseases



## Targeted Neurocircuitry

Cerevel unlocks new treatment opportunities by precisely identifying and targeting the neurocircuitry that underlies a given neuroscience disease.



## Receptor Subtype Selectivity

Cerevel is selectively targeting only the receptor subtype(s) related to the disease physiology, to minimize undesirable off-target effects while maximizing activity.



## Differentiated Pharmacology

Cerevel designs full and partial agonists, antagonists, and allosteric modulators that can precisely fine-tune the receptor pharmacology and neurocircuit activity without over-activation or over-suppression of the endogenous physiologic range.

# OUR PIPELINE

Compound	Mechanism of Action	Disease Area
 Tavapadon	D1/D5 Partial Agonist	Early and Late Parkinson's Disease
 Darigabat	GABA <sub>A</sub> PAM	Epilepsy and Anxiety Disorders
 Emraclidine	M4 PAM	Schizophrenia and Psychosis in Dementia
 CVL-871	D1/D5 Partial Agonist	Dementia-related Apathy
 CVL-354	KOR Antagonist	Major Depressive Disorder and Substance Use Disorder
 CVL-047	PDE4 Inhibitor	Major Depressive Disorder and Schizophrenia
 Candidate Selection	M4 Agonist	Schizophrenia and Psychosis in Dementia
 Candidate Selection	LRRK2 Inhibitor	Parkinson's Disease


Several undisclosed mechanisms, including some with disease-modifying potential

## TAVAPADON



Partial agonist selectively targeting the dopamine D1/D5 receptor with the goal of enhancing motor control and improving tolerability compared to standard of care

## EMRACLIDINE



Selectively targeting the M4 muscarinic receptor with the goal of effectively treating psychosis-related symptoms and improving tolerability compared to standard of care

## DARIGABAT



Selectively targeting specific subunits of the GABA<sub>A</sub> receptor with the goal of providing anticonvulsant and anxiolytic activity with enhanced tolerability and potential for reduced abuse liability

# Partnering with Cerevel

*Together we can make a difference in the lives of those facing some of the most devastating neuroscience diseases*

## Areas of Focus

Cerevel is interested in collaborative partnerships related to novel mechanisms of action with strong genetic links to neuroscience disease pathophysiology, independent of modality. We are also actively scouting for cutting-edge technologies that advance the drug discovery process and increase the probability of clinical success.

We are open to licensing, joint ventures, research collaborations and platform technologies, from biotechnology and pharmaceutical companies, academic institutions, consortiums, and government agencies.

Our targets are rooted in causal human biology with consideration of translational biomarkers predictive of treatment response and disease outcome. The right target, the right pharmacology, the right modality for the right patient population.

## Therapeutic Areas of Interest

### MOVEMENT DISORDERS

- Parkinson's Disease
- Amyotrophic Lateral Sclerosis
- Huntington's Disease

### NEUROPSYCHIATRY

- Schizophrenia
- Anxiety Disorders
- Depression
- Bipolar Disorder
- Cognitive Disorders

### NEUROLOGY

- Epilepsy
- Multiple Sclerosis
- Developmental and Epileptic Encephalopathy
- Pain

### DEMENTIA

- Dementia-related Apathy
- Psychosis Associated with Dementia
- Lewy Body Dementia

## Avenues of Innovation

---



AI/ML augmented applications to identify new targets and perform multi-parameter optimization of small molecules



Imaging tools for target engagement and compound effects



Novel approaches to treat neuroscience diseases such as small molecule RNA modulators



Novel target identification and screening technologies



Ex vivo and in vivo models predictive of disease



Innovative translational biomarker approaches to identify predictive of disease progression, treatment response, and patient stratification



Protein degrader platforms for neuroscience targets



Brain delivery technology to enhance the passage of therapeutics across the blood brain barrier

**Interested in working with us?**

Contact us at [partnering@cerevel.com](mailto:partnering@cerevel.com)

